Peroxisome proliferator-activated receptor-α activator fenofibrate prevents high-fat diet-induced renal lipotoxicity in spontaneously hypertensive rats

Hypertension Research

Volumn 32, Issue 10, 2009, Pages 835-845

  Shin, Seok Joon ^a   Lim, Ji Hee ^a   Chung, Sungjin ^a   Youn, Dong Ye ^a   Chung, Hyun Wha ^a   Kim, Hyung Wook ^a   Lee, Jeong Hwa ^a   Chang, Yoon Sik ^a   Park, Cheol Whee ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; 8 ISOPROSTAGLANDIN F2 ALPHA; ADIPONECTIN; ANGIOTENSIN II; ANGIOTENSINOGEN; DIPEPTIDYL CARBOXYPEPTIDASE; ECTODERMAL DYSPLASIA 1; FATTY ACID; FENOFIBRATE; HEMOGLOBIN A1C; INSULIN; KIDNEY RENIN; LIPID; MEMBRANE PROTEIN; MESSENGER RNA; NITRIC OXIDE; OSTEOPONTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA1; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOAVAILABILITY; BODY FAT; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; GENE EXPRESSION; GLOMERULOSCLEROSIS; GLUCOSE TOLERANCE TEST; HYPERTENSION; INSULIN RESISTANCE; LIPID DIET; LIPID STORAGE; MALE; NEPHRITIS; NEPHROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; RENAL LIPOTOXICITY; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE; URINE LEVEL; WEIGHT GAIN; WISTAR KYOTO RAT;

ADIPONECTIN; ADIPOSE TISSUE; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BLOOD PRESSURE; DIETARY FATS; HEMOGLOBIN A, GLYCOSYLATED; IMMUNOHISTOCHEMISTRY; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; LIPID METABOLISM; MALE; OXIDATIVE STRESS; PPAR ALPHA; PROCETOFEN; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RENIN-ANGIOTENSIN SYSTEM; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 70349984006     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2009.107     Document Type: Article

References (47)

1. Kambham N, Markowitz GS, Valeri AM, Lin J, D'Agati VD. Obesity-related glomerulopathy: An emerging epidemic. Kidney Int 2001; 59: 1498-1509.
2. Rahmouni K, Correia ML, Haynes WG, Mark AL. Obesity-associated hypertension: New insights into mechanisms. Hypertension 2005; 45: 9-14.
3. Rocchini AP. Obesity hypertension. Am J Hypertens 2002; 15: 50S-52S.
4. Sarafidis PA, Bakris GL. Non-esterified fatty acids and blood pressure elevation: A mechanism for hypertension in subjects with obesity/insulin resistance? J Hum Hypertens 2007; 21: 12-21.
5. Dandona P, Mohanty P, Ghanim H, Aljada A, Browne R, Hamouda W, Prabhala A, Afzal A, Garg R. The suppressive effect of dietary restriction and weight loss in the obese on the generation of reactive oxygen species by leukocytes, lipid peroxidation, and protein carbonylation. J Clin Endocrinol Metab 2001; 86: 355-362.
6. Lin KY, Ito A, Asagami T, Tsao PS, Adimoolam S, Kimoto M, Tsuji H, Reaven GM, Cooke JP. Impaired nitric oxide synthase pathway in diabetes mellitus: Role of asymmetrix dimethylarginine and dimetylarginine dimethylaminohydrolase. Circulation 2002; 106: 987-992.
7. Bakker SJ, Ijzerman RG, Teerlink T, Westerhoff HV, Gans RO, Heine RJ. Cytosolic triglycerides and oxidative stress in central obesity: The missing link between excessive atherosclerosis, endothelial dysfunction, and beta-cell failure? Atherosclerosis 2000; 148: 17-21.
8. Schaffer JE. Lipotoxicity: When tissues overeat. Curr Opin Lipidol 2003; 14: 281-287.
9. Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest 2000; 106: 171-176.
10. Fan Q, Liao J, Kobayashi M, Yamashita M, Gu L, Gohda T, Suzuki Y, Wang LN, Horikoshi S, Tomino Y. Candensartan reduced advanced glycation end products accumulation and diminished nito-oxidative stress in type 2 diabetic KK/Ta mice. Nephrol Dial Transplant 2004; 19: 3012-3020.
11. Nangaku M, Miyata T, Sada T, Mizuno M, Inagi R, Ueda Y, Ishikawa N, Yuzawa H, Koike H, van Ypersele de Strihou C, Kurokawa K. Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model. J Am Soc Nephrol 2003; 14: 1212-1222.
12. Sonta T, Inoguchi T, Matsumoto S, Yasukawa K, Inuo M, Tsubouchi H, Sonoda N, Kobayashi K, Utsumi H, Nawata H. In vivo imaging of oxidative stress in the kidney of diabetic mice and its normalization by angiotensin II type 1 receptor blocker. Biochem Biophys Res Commun 2005; 330: 415-422.
13. Paul M, Poyan MA, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev 2006; 86: 747-803.
14. Goossens GH, Blaak EE, van Baak MA. Possible involvement of the adipose tissue renin-angiotensin system in the pathophysiology of obesity and obesity-related disorders. Obes Rev 2003; 4: 43-55.
15. Hall JE, Brands MW, Henegar JR. Mechanisms of hypertension and kidney disease in obesity. Ann NY Acad Sci 1999; 892: 91-107.
16. Guan Y. Peroxisome proliferator-receptive activator family and its relationship to renal complications of the metabolic syndrome. J Am Soc Nephrol 2004; 15: 2801-2815.
17. Costet P, Legendre C, More J, Edgar A, Galtier P, Pineau T. Peroxisome proliferator-activated receptor alpha-isoform deficiency leads to progressive dyslipidemia with sexual dimorphic obesity and steatosis. J Biol Chem 1998; 273: 29577-29585.
18. Diep QN, Touyz RM, Schiffrin EL. Docosahexaenoic acid, a peroxisome proliferator-activated receptor-alpha ligand, induces apoptosis in vascular smooth muscle cells by stimulation of p38 mitogen-activated protein kinase. Hypertension 2000; 36: 851-855.
19. Kintscher U, Lyon C, Wakino S, Bruemmer D, Feng X, Goetze S, Graf K, Moustakas A, Staels B, Fleck E, Hsueh WA, Law RE. PPARalpha inhibits TGF-beta-induced beta5 integrin transcription in vascular smooth muscle cells by interacting with Smad4. Circ Res 2002; 91: E35-e44.
20. Diep QN, Amiri F, Touyz RM, Cohn JS, Endemann D, Neves MF, Schiffrin FL. PPARalpha activator effects on Ang II-induced vascular oxidative stress and inflammation. Hypertension 2002; 40: 866-871.
21. Park CW, Kim HW, Ko SH, Chung HW, Lim SW, Yang CW, Chang YS, Sugawara A, Guan Y, Breyer M. Accelerated diabetic nephropathy in mice lacking the peroxisome proliferator-activated receptor α. Diabetes 2006; 55: 885-893.
22. Park CW, Zhang Y, Cha DR, Su D, Hwang MT, Fan XF, Davis L, Striker G, Zheng F, Breyer MD, Guan YF. PPARα agonist fenofibrate improves diabetic nephropathy in db/db mice. Kidney Int 2006; 69: 511-517.
23. Vera T, Taylor M, Bohman Q, Flasch A, Roman RJ, Stec DE. Fenofibrate prevents the development of angiotensin II-dependent hypertension in mice. Hypertension 2005; 45: 703-735.
24. Zhao X, Li LY. PPAR-α agonist fenofibrate induces renal CYP enzymes and reduces blood pressure and glomerular hypertrophy in Zucker diabetic fatty rats. Am J Nephrol 2008; 28: 598-606.
25. Delaney B, Nicolosi RJ, Wilson TA, Carlson T, Frazer S, Zheng GH, Hess R, Ostergren K, Haworth J, Knutson N. Beta-glucan fractions from barley and oats are similarly antiatherogenic in hypercholesterolemic Syrian golden hamsters. J Nutr 2003; 133: 468-475.
26. Fukada M, Kato S, Miyoshi M, Yamaguchi K, Imoto T, Watanabe T. Systemic administration of lipopolysaccharide upregulates angiotensin II expression in rat renal tubules: Immunohistochemical and ELISA studies. Peptides 2005; 26: 2215-2221.
27. Knight SF, Quigley JE, Yuan J, Roy SS, Elmarakby A, Imig JD. Endothelial dysfunction and the development of renal injury in Spontaneously hypertensive rats fed a high-fat diet. Hypertension 2008; 51 352-359.
28. Sevoda L, Berude J, Gudet D, Dumont M, Tremblay J, Hamet P, Pausova Z. Diet-induced obesity delays cardiovascular recovery from stress in spontaneously hypertensive rats. Obes Res 2004; 12: 1951-1958.
29. Wang MH, Smith A, Zhou Y, Chang HH, Lin S, Zhao X, Imig JD, Dorrance AM. Downregulation of renal CYP-derived eicosanoid synthesis in rats with diet-induced hypertension. Hypertension 2003; 42: 592-599.
30. Barton M, Carmona R, Morawietz H, d'Uscio LV, Goettsch W, Hillen H, Haudenschild CC, Krieger JE, Munter K, Lattmann T, Luscher TF, Shaw S. Obesity is associated with tissue-specific activation of renal angiotensin-converting enzyme in vivo: Evidence for a regulatory role of endothelin. Hypertension 2000; 35: 329-336.
31. Roman RJ, Ma YH, Frohlich B, Markham B. Clofibrate prevents the development of hypertension in Dahl salt-sensitive rats. Hypertension 1993; 21: 985-988.
32. Shatara RK, Quest DW, Wilson TW. Fenofibrate lowers blood pressure in two genetic models of hypertension. Can J Physiol Pharmacol 2000; 78: 367-371.
33. Boustany CM, Bharadwaj K, Daugherty A, Brown DR, Randall DC, Cassis LA. Activation of the systemic and adipose renin-angiotensin system in rats with diet-induced obesity and hypertension. Am J Physiol Regul Integr Comp Physiol 2004; 287: R943-R949.
34. Granger JP, West D, Scott J. Abnormal pressure natriuresis in the dog model of obesity-induced hypertension. Hypertension 1994; 23 (1 Suppl): I8-I11.
35. Chander PN, Gealekman O, Brodsky SV, Elitok S, Tojo A, Crabtree M, Gross SS, Goligorsky MS. Nephropathy in Zucker diabetic fat rat is associated with oxidative and nitrosative stress: Prevention by chronic therapy with a peroxynitrite scavenger ebselen. J Am Soc Nephrol 2004; 15: 2391-2403.
36. Jiang T, Wang Z, Proctor G, Moskowitz S, Liebman SE, Rogers T, Lucia MS, Li J, Levi M. Diet-induced obesity in C57BL/6J mice causes increased renal lipid accumulation and glomerulosclerosis via a sterol regulatory element-binding protein-1c-dependent pathway. J Biol Chem 2005; 280: 32317-32325.
37. Lee HS, Lee JS, Koh HI, Ko KW. Intraglomerular lipid deposition in routine biopsies. Clin Nephrol 1991; 36: 67-75.
38. Watanabe S, Tagawa T, Yamakawa K, Shimabukuro M, Ueda S. Inhibition of the renin-angiotensin system prevents free fatty acid-induced acute endothelial dysfunction in humans. Arterioscler Thromb Vasc Biol 2005; 25: 2376-2380.
39. Mack CM, Moore CX, Jodka CM, Bhavsar S, Wilson JK, Hoyt JA, Roan JL, Vu C, Laugero KD, Parkes DG, Young AA. Antiobesity action of peripheral exenatide (exendin-4) in rodents: Effects on food intake, body weight, metabolic status and side-effect measures. Int J Obes (Lond) 2006; 30: 1332-1340.
40. Henegar JR, Bigler SA, Henegar LK, Tyagi SC, Hall JE. Functional and structural changes in the kidney in the early stages of obesity. J Am Soc Nephrol 2001; 12: 1211-1217.
41. Joles JA, Kunter U, Janssen U, Kriz W, Rabelink TJ, Koomans HA, Floege J. Early mechanisms of renal injury in hypercholesterolemic or hypertriglyceridemic rats. J Am Soc Nephrol 2000; 11: 669-683.
42. Kasiske BL, Crosson JT. Renal disease in patients with massive obesity. Arch Intern Med 1986; 146: 1105-1109.
43. Rodriguez-Iturve B, Romero F, Johnson RJ. Pathophysiological mechanisms of salt-dependent hypertension. Am J Kidney Dis 2007; 50: 655-672.
44. Tsunoda M, Kobayashi N, Ide T, Utsumi M, Nagasawa M, Murakami K. A novel PPARα agonist ameliorates insulin resistance in dogs fed a high-fat diet. Am J Physiol Endocrinol Metab 2008; 294: E833-E840.
45. Kobori H, Nishiyama A. Effects of tempol on renal angiotensinogen production in Dahl salt-sensitive rats. Biochem Biophys Res Commun 2004; 315: 746-750.
46. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ukei K. Adioponectin and adiponectin receptors in obesity-linked insulin resistance. Norvatis Found Symp 2007; 286: 164-176.
47. Schillaci G, Pirro M. Hypoadiponectinemia: A novel link between obesity and hypertension? Hypertension 2007; 49: 1217-1219.